Curient, Immune Checkpoint Inhibitor Theme Rises 7.2%

On the 5th, the immuno-oncology theme rose 3.01% compared to the previous day, showing strength, while Qurient, a stock attracting attention within this theme, surged 7.2% compared to the previous day. Qurient is known as a project management-based bio new drug development venture company.

[Graph] Price Fluctuations of Major Stocks in the Immuno-Oncology Theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Qurient's quant financial score is 12.37 points, ranking 11th within the immuno-oncology theme, with higher stability and profitability scores than the average of other related stocks. This indicates that, from a financial perspective, Qurient's ability to respond to internal and external economic environment changes and its efficient profit-generating capacity are better compared to other stocks in the theme.

[Table] Top Stocks by Financial Score within the Theme


※ The quant financial score is the result of the robo algorithm's analysis based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.